Global COVID-19 treatment trial results published in the New England Journal of Medicine
Interim results of the World Health Organization’s Solidarity Trial, the world’s largest randomized control trial on COVID-19 therapeutics, were published yesterday in the New England Journal of Medicine. The trial has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19, and indicates that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.
The Canadian arm of the Solidarity Therapeutics Trial, called the Canadian Treatments for COVID-19 (CATCO) trial, is led by Dr. Srinivas Murthy at the University of British Columbia in Vancouver and Dr. Robert Fowler at Sunnybrook.
